HURA
TuHURA Biosciences, Inc./NV
Next earnings Aug 14, 2026 · consensus $-0.15 EPS
Last earnings -8.0% on 2026-05-15
$2.16
▼ -16.60%$2.16▼ -14.62%
over 1Y
L $0.44EODHDH $3.25
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-16.6%
1W-20.3%
1M-9.2%
3M+19.3%
YTD+188.0%
1Y-14.6%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy
Conservative balance sheet (liabilities/equity 0.31x).
Revenue (FY2025) $0.00 · FY2025
TuHURA Biosciences, Inc./NV shows $0.00 in FY2025 revenue, and -143.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | -$38.3M | -$22.7M | -$29.3M | -$21.7M | -$30.1M |
| Diluted EPS | — | — | -$2.47 | -$1.21 | -$0.63 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$134M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-21.9%
FCF yield-20.2%
Quality & risk
ROIC (est.)—
Free cash flow-$27.7M
Total debt$34.2K
Net cash$3.59M
Piotroski F-Score2/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+45.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-04-30). Worth a closer look.
Recent filings
all on EDGAR ↗PRE 14APeriod ending 2026-08-182026-06-26open ↗8-KPeriod ending 2026-06-172026-06-17open ↗8-KPeriod ending 2026-05-262026-05-29open ↗4Period ending 2026-05-282026-05-29open ↗10-QPeriod ending 2026-03-312026-05-15open ↗8-KPeriod ending 2026-05-152026-05-15open ↗8-K/APeriod ending 2026-04-022026-04-30open ↗10-K/APeriod ending 2025-12-312026-04-30open ↗8-KPeriod ending 2026-04-212026-04-22open ↗424B5Filing2026-04-08open ↗8-KPeriod ending 2026-04-022026-04-08open ↗8-KPeriod ending 2026-04-012026-04-01open ↗
Frequently asked
- Is TuHURA Biosciences, Inc./NV (HURA) a buy?
- HURA currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.31x).
- What is TuHURA Biosciences, Inc./NV's quality score?
- HURA scores 35.46153846153846/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001498382, latest 10-Q filed 2026-05-15) · EODHD · as of 6/26/2026, 3:12:49 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.